BofA analyst Steve Byrne downgraded DuPont to Underperform from Buy with a price target of $80, up from $78. EPS growth for DuPont has been supported by aggressive share repurchase with EBITDA “more flattish,” says the analyst, who cites what the firm calls a “modest” earnings recovery in 2024 and “under-appreciated” PFAS liabilities for the firm’s double downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DD:
- Chemours, DuPont, Corteva affirm support for PFAS settlement
- DuPont price target raised to $80 from $71 at Citi
- DuPont, Chemours, Corteva reach settlement agreement with state of Ohio
- Chemours, DuPont and Corteva reach settlement agreement with Ohio for $110M
- Appeals court tosses lawsuit against ‘forever chemical’ companies, Axios says
